PUBLISHER: DelveInsight | PRODUCT CODE: 1173623
PUBLISHER: DelveInsight | PRODUCT CODE: 1173623
DelveInsight's 'Paroxysmal Nocturnal Hemoglobinuria(PNH) - Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of Paroxysmal Nocturnal Hemoglobinuria historical and forecasted epidemiology as well as the Paroxysmal Nocturnal Hemoglobinuria market trends in the United States, the EU4 (Germany, France, Italy, Spain), the UK and Japan.
The PNH market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM PNH market size. The report also covers PNH procedure, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032.
Paroxysmal Nocturnal Hemoglobinuria Understanding
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder of the pluripotent hematopoietic stem cell; therefore, it can affect erythrocytes, leukocytes, thrombocytes, and probably some endothelial cells. These hematopoietic stem cells have acquired a somatic mutation in an X-linked gene: the phosphatidylinositol glycan class A (PIG-A). This gene synthesizes the glycosylphosphatidylinositol (GPI) anchor, which is necessary to attach some proteins to the cell membrane.
A clinical polymorphism of PNH has been described. Three forms are identified: classical PNH, PNH associated with aplastic anemia (AA), and subclinical PNH; however, it is important to understand that these entities are three clinical manifestations of a single disease.
The classical form of PNH affects young people preferentially. They suffer from chronic intravascular hemolytic anemia due to a continuous state of complement activation, but brisk periods of hemolysis may result from complement activation due to infection, surgery, strenuous activity, and alcohol intake.in adults. The risk of bleeding correlates to the severity of thrombocytopenia. Patients may present without symptoms, minimal bleeding, or serious hemorrhage (e.g., mucosal, intracranial, gastrointestinal, genitourinary). Older patients, patients on antiplatelet therapy, and patients with comorbid conditions may have severe bleeding manifestations.
When PNH is associated with AA, most patients express only a small PNH clone (<10%). Physicians could find clinical and/or biological evidence of hemolysis associated with two or three cytopenias (Hb <10 g/dL, neutrophils <1,000/μL, platelets <80,000/μL). In general, bone marrow failure dominates the clinical picture.
The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalence of PNH, Gender-specific Prevalence of PNH scenario in the 7MM covering the United States, the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom and Japan from 2019 to 2032.
Iptacopan, or LNP023, is a first-in-class, orally administered, potent, and highly selective factor B inhibitor of the alternative complement pathway. LNP023 is currently in clinical development for PNH and several renal conditions with complement system involvement, including IgA nephropathy, complement 3 glomerulopathies (C3G), atypical hemolytic uremic syndrome, and membranous nephropathy. In PNH, LNP023 acts upstream of the C5 terminal pathway, preventing intravascular hemolysis and extravascular hemolysis. In doing so, LNP023 may have a therapeutic advantage over the current standard of care by targeting the underlying pathophysiology.
Product details in the report…
Crovalimab is also known as RG6107, and SKY59 is a humanized complement inhibitor C5 monoclonal antibody (anti-C5 recycling antibody) discovered by Chugai using recycling antibody technology. SKY59 is designed to target C5, a key component of the complement system, and is expected to control complement activity. It inhibits complement activation by blocking the cleavage of c5 to c5a and c5b, which is the cause of PNH. Roche is codeveloping SKY59 with Chugai Pharmaceuticals.
Products detail in the report…
ALXN2040 (also known as danicopan) is an investigational, first-in-class, oral proximal factor D inhibitor developed by Achillion, a wholly owned subsidiary of Alexion. Factor D (FD), a serine protease, catalyzes the cleavage of complement factor B into Ba and Bb, which allows for the formation of the AP C3 convertase. By inhibiting FD, danicopan, blocks C3 convertase formation, the control point for AP activation, and the amplification of all pathways. This leads to the inhibition of C3 cleavage, C3 fragment deposition, terminal pathway activation, and MAC formation.
PNH is a rare hematological disorder characterized by episodes of hemolysis, thrombosis, and bone marrow failure and sometimes progresses to myelodysplastic syndromes. It has fascinated hematologists for more than a century due to its diverse manifestations and intricate pathophysiology. PNH can sink in 2 ways: one is a classical form called anemia due to hemolysis because of the defect of surface molecules; another is aplastic anemia. In some patients, both of these forms can sink into one another. PNH is typically diagnosed in a nonacute setting.
The disease-modifying therapeutic strategies for PNH are complement inhibition therapy and bone marrow transplantation. Eculizumab is a licensed therapy for PNH, and its efficacy has relegated bone marrow transplantation to second-line therapy for hemolytic PNH in countries where the drug is available. Bone marrow transplantation might be an option if eculizumab is unavailable, and it is a reasonable therapeutic strategy in patients with PNH and severe bone marrow failure. Adjunctive therapies (for example, immunosuppression) could be prescribed to patients with PNH who also have bone marrow failure to ameliorate the latter. However, these adjunctive treatments are not specific to PNH nor have consistent effects on the expansion or reduction of PNH clones. The only curative strategy for PNH is allogeneic stem cell transplantation, but this procedure continues to carry a considerable risk of mortality and is considered for patients who have severe bone marrow failure.
This section provides the total PNH market size and market size by therapies in the United States.
The total PNH market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total PNH market size and market size by therapies in Japan are provided.
This section focuses on the rate of uptake of the potential drugs recently launched in the PNH market or expected to get launched in the market during the study period 2019-2032. The analysis covers the PNH market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.
The report covers detailed information on collaborations, acquisitions, merger, licensing, and patent details for PNH emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
We perform competitive market Intelligence analysis of the PNH market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.